These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 28193529)

  • 1. Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.
    Suda K; Murakami I; Yu H; Kim J; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    J Thorac Oncol; 2017 Jun; 12(6):1015-1020. PubMed ID: 28193529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
    Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.
    Xu Y; Huang Z; Gong L; Fan Y
    Anticancer Drugs; 2017 Oct; 28(9):1056-1061. PubMed ID: 28723866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
    Popat S; Wotherspoon A; Nutting CM; Gonzalez D; Nicholson AG; O'Brien M
    Lung Cancer; 2013 Apr; 80(1):1-4. PubMed ID: 23312887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.
    Watanabe S; Sone T; Matsui T; Yamamura K; Tani M; Okazaki A; Kurokawa K; Tambo Y; Takato H; Ohkura N; Waseda Y; Katayama N; Kasahara K
    Lung Cancer; 2013 Nov; 82(2):370-2. PubMed ID: 24012411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
    Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
    Moreira-Leite FF; Harrison LR; Mironov A; Roberts RA; Dive C
    J Thorac Oncol; 2010 Jun; 5(6):765-77. PubMed ID: 20421816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
    Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T
    Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
    Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.
    Suda K; Rozeboom L; Furugaki K; Yu H; Melnick MAC; Ellison K; Rivard CJ; Politi K; Mitsudomi T; Hirsch FR
    Biomed Res Int; 2017; 2017():7694202. PubMed ID: 29119113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
    Piotrowska Z; Niederst MJ; Karlovich CA; Wakelee HA; Neal JW; Mino-Kenudson M; Fulton L; Hata AN; Lockerman EL; Kalsy A; Digumarthy S; Muzikansky A; Raponi M; Garcia AR; Mulvey HE; Parks MK; DiCecca RH; Dias-Santagata D; Iafrate AJ; Shaw AT; Allen AR; Engelman JA; Sequist LV
    Cancer Discov; 2015 Jul; 5(7):713-22. PubMed ID: 25934077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors].
    Zhang W; Li Y; Wu D
    Zhongguo Fei Ai Za Zhi; 2017 Oct; 20(10):720-726. PubMed ID: 29061221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
    Lee Y; Choi YR; Kim KY; Shin DH
    Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
    Alam N; Gustafson KS; Ladanyi M; Zakowski MF; Kapoor A; Truskinovsky AM; Dudek AZ
    Clin Lung Cancer; 2010 Sep; 11(5):E1-4. PubMed ID: 20837450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
    Onitsuka T; Uramoto H; Nose N; Takenoyama M; Hanagiri T; Sugio K; Yasumoto K
    Lung Cancer; 2010 May; 68(2):198-203. PubMed ID: 19589612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
    Fallet V; Ruppert AM; Poulot V; Lacave R; Belmont L; Antoine M; Cadranel J; Wislez M; Lavolé A
    J Thorac Oncol; 2012 Jun; 7(6):1061-3. PubMed ID: 22588159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.